

10/657,812

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America
NEWS 5 AUG 30 CA/Caplus -Increased access to 19th century research documents
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03 MATHDI removed from STN
NEWS 9 OCT 04 CA/Caplus-Canadian Intellectual Property Office (CIPO) added
to core patent offices
NEWS 10 OCT 06 STN AnaVist workshops to be held in North America
NEWS 11 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download
of Caplus documents for use in third-party analysis and
visualization tools
NEWS 13 OCT 27 Free KWIC format extended in full-text databases
NEWS 14 OCT 27 DIOGENES content streamlined
NEWS 15 OCT 27 EPFULL enhanced with additional content

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:34:29 ON 13 NOV 2005

Page 2

=> d his

(FILE 'HOME' ENTERED AT 18:34:29 ON 13 NOV 2005)

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.10

2.10

FILE 'REGISTRY' ENTERED AT 18:40:26 ON 13 NOV 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 NOV 2005 HIGHEST RN 867335-63-5

DICTIONARY FILE UPDATES: 11 NOV 2005 HIGHEST RN 867335-63-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information.  *
*                                                                      *
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

Page 2

=>

Uploading C:\Program Files\Stnexp\Queries\10657812b.str

L1 STRUCTURE UPLOADED

=>


Uploading C:\Program Files\Stnexp\Queries\10657812c.str

L2 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 12

L2 HAS NO ANSWERS

L2 STR



G1 CF2,CCl2,CBr2,SO2,CN,NO2,[@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 18:41:06 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s 12

SAMPLE SEARCH INITIATED 18:41:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 229 TO 851
PROJECTED ANSWERS: 8 TO 329

L4 8 SEA SSS SAM L2

=> search 11

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 18:41:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 87 TO ITERATE

100.0% PROCESSED 87 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

L5 12 SEA SSS FUL L1

=> search 12

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 18:41:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 475 TO ITERATE

100.0% PROCESSED 475 ITERATIONS 144 ANSWERS
SEARCH TIME: 00.00.01

L6 144 SEA SSS FUL L2

=> file caplus

| | | |
|----------------------|------------|---------|
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL |
| | ENTRY | SESSION |
| FULL ESTIMATED COST | 322.66 | 324.76 |

FILE 'CAPLUS' ENTERED AT 18:41:31 ON 13 NOV 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Nov 2005 VOL 143 ISS 21
 FILE LAST UPDATED: 11 Nov 2005 (20051111/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15 or 16

8 L5

5 L6

L7 9 L5 OR L6

=> d 17 fbib ab hitstr 1-9

L7 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:220311 CAPLUS
 DN 140:271195
 TI Preparation of N'-arylaminothioyl glycinamides as glycine transport inhibitors for treating pain and spasticity
 IN Isaac, Methvin; Xin, Tao; Stefanac, Tomaslav; O'Brien, Anne; Da Silva, Kathleen; Arora, Jalaj; Maddaford, Shawn; Slassi, Abdelmalik
 PA Nps Allelix Corp., Can.
 SO PCT Int. Appl., 173 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|--|------|----------|-----------------|------------|
| PI | WO 2004022534 | A1 | 20040318 | WO 2003-CA1370 | 20030909 |
| | W: | | | | |
| | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: | | | | |
| | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | US 2002-409420P | P 20020909 |

US 2004152740

A1

20040805

US 2003-657812

20030908

US 2002-409420P

P 20020909


OS MARPAT 140:271195

AB The present invention relates to $R_1NHC(O)CR_2R_3NHC(S)NHArl$ (I; e.g. N-(2,6-dimethylphenyl)-2-[3-[4-(dimethylsulfamoyl)-2-nitrophenyl]thioureido]-2-phenylacetamide (II)) and salts, solvates and hydrates thereof. The invention further relates to pharmaceutical compns. containing said compds. and methods of treating neurol. and neuropsychiatric disorders using said compds. IC50 values for 15 examples of I for inhibiting the GlyT-2 glycine transporter are tabulated, e.g. 14.22 nM for II. Although the methods of preparation are not claimed, many example preps. are included. For example, II was prepared in 94% yield from 2-amino-N-(2,6-dimethylphenyl)-2-phenylacetamide and 2-nitro-4-(dimethylsulfamoyl)phenyl isothiocyanate. For I: R_1 = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; wherein R_1 is (un)substituted with ≥ 1 substituents R_a ; wherein R_a = alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, aryl, heteroaryl, aralkyl, heteroaralkyl and $-(R_7)nNR_8R_9$ (R_7 = alkyl, alkoxy, and oxyalkyl, R_8 and R_9 = H, and alkyl, or R_8 and R_9 can join together such that NR_8R_9 form a 5 or 6-member heterocyclic ring, and $n = 0-3$) wherein the substituent(s) R_a is optionally further substituted with ≥ 1 substituents = alkyl, alkoxy, halo, cyano, alkanoyl, haloalkyl, thioalkyl, nitro, and $-(R_7)nNR_8R_9$. R_2 and R_3 are: (a) independently H, alkyl, aralkyl (un)substituted aryl, (un)substituted heteroaryl and (un)substituted, (un)saturated, 5- or 6-membered, homocyclic or heterocyclic rings wherein the optional substituent may be H, alkyl, alkoxy, and halo; or (b) joined together to form a 3-7 member spirocyclic ring. Ar_1 is aryl and is (un)substituted with ≥ 1 substituents R_b = alkyl, alkoxy, halo, haloalkyl, nitro, $-(R_7)nNR_8R_9$, alkanoyl, aryl, heteroaryl, $-O(CH_2)_mNR_{10}R_{11}$ and $-SO_2NR_{10}R_{11}$ (R_7 = alkyl, alkoxy and oxyalkyl; R_8 and R_9 = H, and alkyl, or R_8 and R_9 can join together such that NR_8R_9 form a 5 or 6-member heterocyclic ring, and $n = 0-3$) and the groups R_{10} and R_{11} = H, or alkyl, or groups R_{10} and R_{11} can join together such that $NR_{10}R_{11}$ form a 5 or 6-member ring, and $m = 1-5$; R_b are optionally further substituted. When Ar_1 is Ph then (a) Ar_1 has a substituent R_b at the 2-position wherein the substituent = nitro, haloalkyl, cyano, $-C(O)R_{12}$ $-C(O)OR_{12}$, $-C(O)NR_{12}R_{12}$, $-S(O)R_{12}$, $-S(O)R_{12}$, and $-S(O)NR_{12}R_{13}$ (wherein R_{12} and R_{13} = H and alkyl) or (b) Ar_1 has an alkanoyl substituent at the 4-position.

IT 672961-09-0P, N-(2,6-Dimethylphenyl)-2-[3-[4-[2-(N,N-dimethylamino)ethoxy]-2-nitrophenyl]thioureido]-2-phenylacetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of N'-arylaminothioyl glycinamides as glycine transport inhibitors for treating pain and spasticity)

RN 672961-09-0 CAPLUS

CN Benzeneacetamide, α -[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT 672959-44-3P, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-methylacetamide 672959-52-3P, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide 672959-57-8P, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide 672959-62-5P, (S)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-isopropylacetamide 672959-67-0P, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672959-68-1P, N-(2-Methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-phenylacetamide 672959-69-2P, N-(2-Methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide 672959-70-5P, N-(2-Methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672959-72-7P, N-(2-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide 672959-73-8P, N-(2-Methylphenyl)-2-[3-[4-(2-N,N-dimethylaminoethoxy)-2-nitrophenyl]thioureido]-2-phenylacetamide 672959-79-4P, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672959-80-7P, (R)-N-(2-Methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide 672959-97-6P, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-benzylacetamide 672960-01-9P 672960-16-6P, (S)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-cyclohexylacetamide 672960-18-8P, (R)-N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-cyclohexylacetamide 672960-24-6P, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(2-methylpropyl)acetamide 672960-33-7P, N-(2-Methoxycarbonylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-34-8P, N-(2-Methoxycarbonylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide 672960-35-9P, N-(2-Methoxycarbonylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-38-2P, N-(2-Cyanophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-41-7P, N-(2-Methoxyphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-42-8P, N-(2-Methoxyphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide 672960-43-9P, N-(2-Methoxyphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-46-2P, N-(2-Methylthiophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-47-3P, N-(2-Methylthiophenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide 672960-48-4P, N-(2-Methylthiophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-51-9P, N-(2-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-52-0P, N-(2-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide 672960-53-1P, N-(2-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-56-4P, N-(3-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-57-5P, N-(3-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-58-6P, N-(3-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide 672960-61-1P, N-(4-Chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-62-2P, N-(4-Chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-63-3P, N-(4-Chlorophenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide 672960-66-6P, N-(2,3-Dimethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-67-7P, N-(2,3-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide 672960-70-2P, N-(5,6,7,8-Tetrahydronaphthalen-1-yl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide 672960-71-3P


, N-(5,6,7,8-Tetrahydronaphthalen-1-yl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-74-6P**,
 , N-(2-Methyl-4-chlorophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-75-7P**, N-(2-Methyl-4-chlorophenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-78-0P**,
 N-(5-Phenyl-2-methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-79-1P**,
 N-(5-Phenyl-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-82-6P**, N-(4-Phenyl-2-methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672960-83-7P**,
 N-(4-Phenyl-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672960-85-9P**, N-(6-Ethyl-2-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-88-2P**,
 , N-(2-Isopropyl-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-91-7P**, N-(2-Chloro-6-methylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-94-0P**,
 N-(2,4-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672960-97-3P**,
 N-(2,5-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-00-1P**, N-(2-Methyl-1-naphthyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-02-3P**,
 , N-(2,6-Dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-03-4P**, N-(2,6-Dimethylphenyl)-2-[3-[2-[(N,N-dimethylamino)sulfonyl]phenyl]thioureido]-2-phenylacetamide **672961-05-6P**,
 N-(2,6-Dimethylphenyl)-2-[3-(2-N-methylpiperazin-1-ylsulfonylphenyl)thioureido]-2-phenylacetamide **672961-10-3P**,
 N-(2,6-Dimethylphenyl)-2-[3-[2-nitro-4-[2-(N,N-dimethylamino)ethoxy]phenyl]thioureido]-2-phenylacetamide hydrochloride **672961-12-5P**,
 N-(2,6-Dimethylphenyl)-2-[3-[4-[(N,N-dimethylamino)sulfonyl]-2-nitrophenyl]thioureido]-2-phenylacetamide **672961-13-6P**,
 N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-14-7P**,
 N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-17-0P**, N-(2,6-Dimethylphenyl)-2-[3-[4-(2-N,N-dimethylaminoethoxy)-2-trifluoromethylphenyl]thioureido]-2-phenylacetamide **672961-21-6P**,
 N-(2,6-Dimethylphenyl)-2-[3-[4-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-2-trifluoromethylphenyl]thioureido]-2-phenylacetamide **672961-22-7P**,
 N-(2,6-Dimethylphenyl)-2-[3-(4-methyl-2-nitrophenyl)thioureido]-2-phenylacetamide **672961-23-8P**,
 N-(2,6-Dimethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-38-5P**,
 N-(4-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-39-6P**,
 N-(4-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-40-9P**,
 N-(Phenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-41-0P**,
 N-(Phenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-46-5P**,
 N-(3-Methylphenyl)-2-[3-(1-naphthyl)thioureido]-2-phenylacetamide **672961-47-6P**,
 N-(3-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-57-8P**,
 (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-cyclohexylacetamide **672961-58-9P**,
 (R)-N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-cyclohexylacetamide **672961-59-0P**,
 N-(2-Isopropylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-phenylacetamide **672961-61-4P**,
 , N-(2-Isopropylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-62-5P**,
 N-(2-Isopropylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-63-6P**,
 , N-(2-Phenylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-67-0P**,
 N-(1-Naphthyl)-2-[3-(2-nitrophenyl)thioureido]-2-

phenylacetamide **672961-68-1P**, N-[2-(4-Methylpiperazin-1-yl)phenyl]-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672961-70-5P**, N-[2-(4-Methylpiperazin-1-yl)phenyl]-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-73-8P**, N-(2-Methylphenyl)-2-[3-(2-nitro-4-methoxyphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-74-9P**, N-(2-Methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-76-1P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672961-81-8P**, N-(2-Methylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-(3-trifluoromethylphenyl)acetamide **672961-87-4P**, N-(2-Methylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-88-5P**, N-(2-Methylphenyl)-2-[3-(2-methoxy-5-nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-89-6P**, N-(2-Methylphenyl)-2-[3-(3-trifluoromethylphenyl)thioureido]-2-(3-thienyl)acetamide **672961-90-9P**, N-(2-Methylphenyl)-2-[3-(2-Nitrophenyl)thioureido]-2-(3-thienyl)acetamide **672961-93-2P**, N-(2-Trifluoromethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-94-3P**, N-(2-Ethylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672961-99-8P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-4-methylpentanamide **672962-00-4P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-4-methylpentanamide **672962-01-5P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-(4-ethoxy-2-nitrophenyl)thioureido]-4-methylpentanamide **672962-02-6P**, (R)-N-(2,6-Dimethylphenyl)-2-[3-[4-(2-dimethylaminoethoxy)-2-nitrophenyl]thioureido]-4-methylpentanamide **672962-05-9P**, N-(5-Methoxy-2-methylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-phenylacetamide **672962-10-6P**, N-(2,6-Dimethylphenyl)-2-[3-(4-methoxy-2-nitrophenyl)thioureido]-2-(3,4-difluorophenyl)acetamide **672962-15-1P**, N-(4-Isopropylphenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672962-17-3P**, N-(4-Nitrophenyl)-2-[3-(2-nitrophenyl)thioureido]-2-phenylacetamide **672962-19-5P**, N-(2,6-Dimethylphenyl)-2-[3-(2-trifluoromethylphenyl)thioureido]-2-(3,4-difluorophenyl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of N'-arylaminothiocarbonyl glycinamides as glycine transport inhibitors for treating pain and spasticity)


RN 672959-44-3 CAPLUS

CN Propanamide, N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672959-52-3 CAPLUS

CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672959-57-8 CAPLUS
 CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672959-62-5 CAPLUS
 CN Butanamide, 3-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672959-67-0 CAPLUS
 CN Benzeneacetamide, N-(2-methylphenyl)-alpha-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672959-68-1 CAPLUS
 CN Benzeneacetamide, alpha-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672959-69-2 CAPLUS

CN Benzeneacetamide, α -[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672959-70-5 CAPLUS

CN Benzeneacetamide, N-(2-methylphenyl)- α -[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672959-72-7 CAPLUS

CN Benzeneacetamide, N-(2-methylphenyl)- α -[[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672959-73-8 CAPLUS


CN Benzeneacetamide, α -[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 672959-79-4 CAPLUS

CN Benzeneacetamide, N-(2-methylphenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672959-80-7 CAPLUS

CN Benzeneacetamide, α -[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672959-97-6 CAPLUS


CN Benzenepropanamide, N-(2-methylphenyl)- α -[[[(2-

nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)



RN 672960-01-9 CAPLUS


CN Propanamide, 2-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)



RN 672960-16-6 CAPLUS

CN Cyclohexaneacetamide, N-(2-methylphenyl)-alpha-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (alphaS) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 672960-18-8 CAPLUS

CN Cyclohexaneacetamide, N-(2-methylphenyl)-alpha-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-, (alphaR) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 672960-24-6 CAPLUS
 CN Pentanamide, 4-methyl-N-(2-methylphenyl)-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-33-7 CAPLUS
 CN Benzoic acid, 2-[[[[[(2-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 672960-34-8 CAPLUS
 CN Benzoic acid, 2-[[[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 672960-35-9 CAPLUS
 CN Benzoic acid, 2-[[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]acetyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 672960-38-2 CAPLUS
 CN Benzeneacetamide, N-(2-cyanophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-41-7 CAPLUS
 CN Benzeneacetamide, N-(2-methoxyphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672960-42-8 CAPLUS
 CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 672960-43-9 CAPLUS
 CN Benzeneacetamide, N-(2-methoxyphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-46-2 CAPLUS

CN Benzeneacetamide, N-[2-(methylthio)phenyl]- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-47-3 CAPLUS

CN Benzeneacetamide, α -[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(methylthio)phenyl] - (9CI) (CA INDEX NAME)




RN 672960-48-4 CAPLUS

CN Benzeneacetamide, N-[2-(methylthio)phenyl]- α -[[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-51-9 CAPLUS

CN Benzeneacetamide, N-(2-chlorophenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-52-0 CAPLUS

CN Benzeneacetamide, N-(2-chlorophenyl)- α -[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-53-1 CAPLUS

CN Benzeneacetamide, N-(2-chlorophenyl)- α -[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-56-4 CAPLUS

CN Benzeneacetamide, N-(3-chlorophenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-57-5 CAPLUS

CN Benzeneacetamide, N-(3-chlorophenyl)- α -[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-58-6 CAPLUS

CN Benzeneacetamide, N-(3-chlorophenyl)- α -[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-61-1 CAPLUS

CN Benzeneacetamide, N-(4-chlorophenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-62-2 CAPLUS

CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-63-3 CAPLUS

CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[[4-methoxy-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-66-6 CAPLUS

CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-67-7 CAPLUS

CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-70-2 CAPLUS

CN Benzeneacetamide, α -[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 672960-71-3 CAPLUS

CN Benzeneacetamide, N-(5,6,7,8-tetrahydro-1-naphthalenyl)- α -[[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-74-6 CAPLUS

CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-75-7 CAPLUS

CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-78-0 CAPLUS

CN Benzeneacetamide, N-(4-methyl[1,1'-biphenyl]-3-yl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-79-1 CAPLUS

CN Benzeneacetamide, N-(4-methyl[1,1'-biphenyl]-3-yl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-82-6 CAPLUS

CN Benzeneacetamide, N-(3-methyl[1,1'-biphenyl]-4-yl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-83-7 CAPLUS

CN Benzeneacetamide, N-(3-methyl[1,1'-biphenyl]-4-yl)-α-[[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-85-9 CAPLUS

CN Benzeneacetamide, N-(2-ethyl-6-methylphenyl)-α-[[[4-methoxy-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-88-2 CAPLUS

CN Benzeneacetamide, α-[[[4-methoxy-2-nitrophenyl]amino]thioxomethyl]amino]-N-[2-methyl-6-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672960-91-7 CAPLUS

CN Benzeneacetamide, N-(2-chloro-6-methylphenyl)-α-[[[4-methoxy-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672960-94-0 CAPLUS

CN Benzeneacetamide, N-(2,4-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672960-97-3 CAPLUS

CN Benzeneacetamide, N-(2,5-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-00-1 CAPLUS

CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methyl-1-naphthalenyl) - (9CI) (CA INDEX NAME)




RN 672961-02-3 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)- α -[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-03-4 CAPLUS

CN Benzeneacetamide, α -[[[2-[(dimethylamino)sulfonyl]phenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 672961-05-6 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)- α -[[[2-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-10-3 CAPLUS

CN Benzeneacetamide, α -[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 672961-12-5 CAPLUS
CN Benzeneacetamide, α -[[[4-[(dimethylamino)sulfonyl]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 672961-13-6 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)- α -[[[4-methoxy-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-14-7 CAPLUS
CN Benzeneacetamide, N-(2,6-dimethylphenyl)- α -[[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-17-0 CAPLUS
CN Benzeneacetamide, α -[[[4-[2-(dimethylamino)ethoxy]-2-(trifluoromethyl)phenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 672961-21-6 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[4-(1,2,3,6-tetrahydro-1-methyl-4-pyridinyl)-2-(trifluoromethyl)phenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-22-7 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[4-methyl-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-23-8 CAPLUS

CN Benzeneacetamide, N-(4-methylphenyl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-38-5 CAPLUS

CN Benzeneacetamide, N-(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-39-6 CAPLUS

CN Benzeneacetamide, N-(4-methylphenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-40-9 CAPLUS

CN Benzeneacetamide, α -[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 672961-41-0 CAPLUS

CN Benzeneacetamide, α -[[[(1-naphthalenylamino)thioxomethyl]amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 672961-46-5 CAPLUS

CN Benzeneacetamide, N-(3-methylphenyl)-α-[[[(1-naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-47-6 CAPLUS


CN Benzeneacetamide, N-(3-methylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-57-8 CAPLUS


CN Cyclohexaneacetamide, N-(2,6-dimethylphenyl)-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672961-58-9 CAPLUS
 CN Cyclohexaneacetamide, N-(2,6-dimethylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672961-59-0 CAPLUS
 CN Benzeneacetamide, α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672961-61-4 CAPLUS
 CN Benzeneacetamide, N-[2-(1-methylethyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-62-5 CAPLUS

CN Benzeneacetamide, N-[2-(1-methylethyl)phenyl]-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-63-6 CAPLUS

CN Benzeneacetamide, N-[1,1'-biphenyl]-2-yl-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-67-0 CAPLUS

CN Benzeneacetamide, N-1-naphthalenyl-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-68-1 CAPLUS

CN Benzeneacetamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-70-5 CAPLUS

CN Benzeneacetamide, N-[2-(4-methyl-1-piperazinyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-73-8 CAPLUS

CN Benzeneacetamide, 3,4-difluoro-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl) - (9CI) (CA INDEX NAME)




RN 672961-74-9 CAPLUS

CN Benzeneacetamide, 3,4-difluoro-N-(2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-76-1 CAPLUS

CN Benzeneacetamide, 3,4-difluoro-N-(2-methylphenyl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672961-81-8 CAPLUS

CN Benzeneacetamide, N-(2-methylphenyl)-α-[[[2-nitrophenyl]amino]thioxomethyl]amino]-3-(trifluoromethyl) - (9CI) (CA INDEX NAME)




RN 672961-87-4 CAPLUS

CN 3-Thiopheneacetamide, α-[[[(4-ethoxy-2-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl) - (9CI) (CA INDEX NAME)




RN 672961-88-5 CAPLUS

CN 3-Thiopheneacetamide, α -[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672961-89-6 CAPLUS

CN 3-Thiopheneacetamide, N-(2-methylphenyl)- α -[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-90-9 CAPLUS

CN 3-Thiopheneacetamide, N-(2-methylphenyl)- α -[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672961-93-2 CAPLUS

CN Benzeneacetamide, α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672961-94-3 CAPLUS


CN Benzeneacetamide, N-(2-ethylphenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672961-99-8 CAPLUS

CN Pentanamide, N-(2,6-dimethylphenyl)-4-methyl-2-[[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672962-00-4 CAPLUS

CN Pentanamide, N-(2,6-dimethylphenyl)-2-[[[(4-methoxy-2-

nitrophenyl)amino]thioxomethyl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672962-01-5 CAPLUS

CN Pentanamide, N-(2,6-dimethylphenyl)-2-[[[4-ethoxy-2-nitrophenyl]amino]thioxomethyl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672962-02-6 CAPLUS


CN Pentanamide, 2-[[[4-[2-(dimethylamino)ethoxy]-2-nitrophenyl]amino]thioxomethyl]amino]-N-(2,6-dimethylphenyl)-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672962-05-9 CAPLUS

CN Benzeneacetamide, N-(5-methoxy-2-methylphenyl)-α-[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)




RN 672962-10-6 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-3,4-difluoro-α-[[[(4-methoxy-2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)




RN 672962-15-1 CAPLUS

CN Benzeneacetamide, N-[4-(1-methylethyl)phenyl]-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)



RN 672962-17-3 CAPLUS


CN Benzeneacetamide, N-(4-nitrophenyl)-α-[[[(2-nitrophenyl)amino]thioxomethyl]amino] - (9CI) (CA INDEX NAME)



RN 672962-19-5 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-3,4-difluoro-α-[[thioxo[[2-

(trifluoromethyl)phenyl]amino]methyl]amino] - (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:220306 CAPLUS
DN 140:271194
TI Arylglycine derivatives and their use as glycine transport inhibitors
IN Isaac, Methvin; Xin, Tao; Edwards, Louise; Begleiter, Leah; Stefanac, Tomaslav; O'Brien, Anne; Da Silva, Kathleen; Arora, Jalaj; Maddaford, Shawn; Slassi, Abdelmalik
PA Nps Allelix Corp., Can.
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---------------|--|----------|-----------------|------------|
| PI | WO 2004022528 | A2 | 20040318 | WO 2003-CA1369 | 20030909 |
| | WO 2004022528 | A3 | 20040521 | | |
| | W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| | RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| | | | | US 2002-409421P | P 20020909 |
| | US 2004152741 | A1 | 20040805 | US 2003-657815 | 20030908 |
| | | | | US 2002-409421P | P 20020909 |

OS MARPAT 140:271194

AB The invention relates to compds. R₁NHCOCR₂R₃NHC(:X)NHA₁ [R₁ is (un)substituted (hetero)cycloalkyl or (hetero)aryl; R₂, R₃ are H, alkyl, haloalkyl, aralkyl, or a group given for R₁; X is O, S, NH, or NCN; A₁ is aryl (with provisos)] and their salts, solvates, and hydrates for treating neurol., neuropsychiatric, and gastrointestinal disorders. Thus, N-(indan-5-yl)-2-[3-(2-methoxy-5-nitrophenyl)thioureido]-2-(3-thienyl)acetamide (claimed compound) was prepared by condensation of (±)-3-thienylglycine indan-5-ylamide (preparation given) with 2-methoxy-5-nitrophenyl isocyanate and showed IC₅₀ = 131.448 nM for

glycine uptake.


IT 672961-38-5P 672962-37-7P 672962-43-5P
 672962-48-0P 672962-52-6P 672962-53-7P
 672962-58-2P 672962-59-3P 672962-60-6P
 672962-61-7P 672962-62-8P 672962-63-9P
 672962-64-0P 672962-67-3P 672962-68-4P
 672962-69-5P 672962-80-0P 672962-81-1P
 672962-82-2P 672962-85-5P 672962-86-6P
 672962-89-9P 672962-94-6P 672962-97-9P
 672963-00-7P 672963-04-1P 672963-05-2P
 672963-11-0P 672963-15-4P 672963-19-8P
 672963-20-1P 672963-27-8P 672963-32-5P
 672963-36-9P 672963-37-0P 672963-45-0P
 672963-47-2P 672963-48-3P 672963-52-9P
 672963-53-0P 672963-61-0P 672963-70-1P
 672963-74-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of arylglycine derivs. as inhibitors of glycine transport in
 treatment of neurol. and gastrointestinal disorders)


RN 672961-38-5 CAPLUS

CN Benzeneacetamide, N-(4-methylphenyl)- α -[[[(1-
 naphthalenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-37-7 CAPLUS

CN Benzeneacetamide, α -[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]a
 mino]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672962-43-5 CAPLUS

CN Benzeneacetamide, N-(2-methylphenyl)-α-[[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-48-0 CAPLUS

CN Cyclohexaneacetamide, N-(2-methylphenyl)-α-[[[(3-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-52-6 CAPLUS

CN Benzeneacetamide, N-(3-chlorophenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-53-7 CAPLUS

CN Benzeneacetamide, N-(4-chlorophenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-58-2 CAPLUS

CN Benzeneacetamide, N-(2,3-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-(9CI) (CA INDEX NAME)




RN 672962-59-3 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(5,6,7,8-tetrahydro-1-naphthalenyl)-(9CI) (CA INDEX NAME)




RN 672962-60-6 CAPLUS

CN Benzeneacetamide, N-(4-chloro-2-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-(9CI) (CA INDEX NAME)




RN 672962-61-7 CAPLUS

CN Benzeneacetamide, N-(2-ethyl-6-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-62-8 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[2-methyl-6-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-63-9 CAPLUS

CN Benzeneacetamide, N-(2-chloro-6-methylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-64-0 CAPLUS

CN Benzeneacetamide, N-(2,4-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-67-3 CAPLUS

CN Benzeneacetamide, N-(2,6-dimethylphenyl)-α-[[[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-nitrophenyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672962-68-4 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672962-69-5 CAPLUS

CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 672962-80-0 CAPLUS


CN Benzeneacetamide, 3,4-difluoro-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-81-1 CAPLUS
 CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-3-(trifluoromethyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 672962-82-2 CAPLUS
 CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-85-5 CAPLUS
 CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-86-6 CAPLUS

CN Benzeneacetamide, α -[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-89-9 CAPLUS

CN Benzeneacetamide, α -[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672962-94-6 CAPLUS

CN Benzeneacetamide, α -[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-8-quinolinyl- (9CI) (CA INDEX NAME)




RN 672962-97-9 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-methyl-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672963-00-7 CAPLUS

CN Benzeneacetamide, N-[3-(dimethylamino)phenyl]-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672963-04-1 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-6-quinolinyl- (9CI) (CA INDEX NAME)




RN 672963-05-2 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 672963-11-0 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 672963-15-4 CAPLUS

CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 672963-19-8 CAPLUS


CN Benzeneacetamide, N-(2,3-dihydro-1H-inden-5-yl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672963-20-1 CAPLUS
 CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(2,3-dihydro-1H-inden-5-yl)- (9CI) (CA INDEX NAME)



RN 672963-27-8 CAPLUS
 CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-2-naphthalenyl- (9CI) (CA INDEX NAME)




RN 672963-32-5 CAPLUS
 CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 672963-36-9 CAPLUS

CN Benzeneacetamide, α -[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(3,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 672963-37-0 CAPLUS


CN Benzeneacetamide, N-(3,4-dimethylphenyl)- α -[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-45-0 CAPLUS


CN Benzeneacetamide, N-(3,4-dimethylphenyl)- α -[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672963-47-2 CAPLUS

CN Benzeneacetamide, α -[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 672963-48-3 CAPLUS

CN Benzeneacetamide, N-(3,5-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




RN 672963-52-9 CAPLUS

CN Benzeneacetamide, α-[[[(2-chloro-5-nitrophenyl)amino]thioxomethyl]amino]-N-(4-ethenylphenyl)- (9CI) (CA INDEX NAME)



RN 672963-53-0 CAPLUS


CN Benzeneacetamide, N-(4-ethenylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-61-0 CAPLUS


CN Benzeneacetamide, α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]a

mino]-N-[6-(trifluoromethyl)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 672963-70-1 CAPLUS

CN 3-Thiopheneacetamide, N-(3,4-dimethylphenyl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 672963-74-5 CAPLUS

CN 3-Thiopheneacetamide, N-(2,3-dihydro-1H-inden-5-yl)-α-[[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)




IT 672963-62-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylglycine derivs. as inhibitors of glycine transport in treatment of neurol. and gastrointestinal disorders)

RN 672963-62-1 CAPLUS

CN Benzeneacetamide, N-(4-bromophenyl)- α -[[(2-methoxy-5-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:757692 CAPLUS

DN 139:261159

TI Preparation of cyclic hemiacetal derivative and use thereof

IN Nakamura, Masayuki; Inoue, Jun

PA Senju Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|------------|
| PI | WO 2003078415 | A1 | 20030925 | WO 2003-JP3122 | 20030314 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | | | | JP 2002-72762 | A 20020315 |
| EP | 1489076 | A1 | 20041222 | EP 2003-712708 | 20030314 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| | | | | JP 2002-72762 | A 20020315 |
| | | | | WO 2003-JP3122 | W 20030314 |
| US | 2005119499 | A1 | 20050602 | US 2003-507831 | 20030314 |
| | | | | JP 2002-72762 | A 20020315 |
| | | | | WO 2003-JP3122 | W 20030314 |

OS MARPAT 139:261159

AB The patent relates to the preparation of calpain inhibitor cyclic hemiacetal compound I (R1 = lower alkyl; R2 = H, halo, cyano, lower alkyl, lower alkoxy; n = 0, 1). A title compound I (n = 0, R1 = iCH2CHMe2, R2 = H), prepared by reduction of the corresponding oxo-precursor with

diisobutylaluminium hydride, was formulated in a eye drop composition

IT 602307-54-0P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclic hemiacetal derivative having calpain inhibitive activity)

RN 602307-54-0 CAPLUS

CN Pentanamide, 2-[[[(3-cyanophenyl)amino]thioxomethyl]amino]-4-methyl-N-[(3S)-tetrahydro-2-hydroxy-3-furanyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1995:789155 CAPLUS

DN 123:199414

TI Preparation of peptidyllactol derivatives as inhibitors of cathepsin L.

IN Sohda, Takashi; Fujisawa, Yukio; Oi, Satoru; Mizoguchi, Junji

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 54 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|------------|
| PI | EP 641800 | A1 | 19950308 | EP 1994-113669 | 19940901 |
| | EP 641800 | B1 | 20020116 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| | | | | JP 1993-219655 | A 19930903 |
| | | | | JP 1994-168501 | A 19940720 |
| | | | | JP 1994-190385 | A 19940812 |
| | NO 9403210 | A | 19950306 | NO 1994-3210 | 19940830 |
| | | | | JP 1993-219655 | A 19930903 |
| | | | | JP 1994-168501 | A 19940720 |
| | | | | JP 1994-190385 | A 19940812 |
| | JP 08104685 | A2 | 19960423 | JP 1994-208981 | 19940901 |
| | | | | JP 1993-219655 | A 19930903 |
| | | | | JP 1994-168501 | A 19940720 |
| | | | | JP 1994-190385 | A 19940812 |
| | AT 212036 | E | 20020215 | AT 1994-113669 | 19940901 |
| | | | | JP 1993-219655 | A 19930903 |
| | | | | JP 1994-168501 | A 19940720 |

| | | | | | |
|------------|----|----------|-----------------|---|----------|
| CA 2131397 | AA | 19950304 | JP 1994-190385 | A | 19940812 |
| | | | CA 1994-2131397 | | 19940902 |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-168501 | A | 19940720 |
| | | | JP 1994-190385 | A | 19940812 |
| FI 9404040 | A | 19950304 | FI 1994-4040 | | 19940902 |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-168501 | A | 19940720 |
| | | | JP 1994-190385 | A | 19940812 |
| AU 9471682 | A1 | 19950316 | AU 1994-71682 | | 19940902 |
| AU 678493 | B2 | 19970529 | | | |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-168501 | A | 19940720 |
| | | | JP 1994-190385 | A | 19940812 |
| HU 68717 | A2 | 19950728 | HU 1994-2536 | | 19940902 |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-168501 | A | 19940720 |
| | | | JP 1994-190385 | A | 19940812 |
| CN 1106001 | A | 19950802 | CN 1994-115669 | | 19940902 |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-190385 | A | 19940812 |
| US 5496834 | A | 19960305 | US 1994-300738 | | 19940902 |
| | | | JP 1993-219655 | A | 19930903 |
| | | | JP 1994-168501 | A | 19940720 |
| | | | JP 1994-190385 | A | 19940812 |

OS CASREACT 123:199414; MARPAT 123:199414

AB Title compds. [I; Q = 1-2 (substituted) amino acid residues; R3 = (esterified) carboxyl, acyl; A = alkylene; B = H, (substituted) alkyl, acyl], were prepared. Thus, N-benzyloxycarbonylhomoserine, 1-hydroxybenzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide were stirred 14 h in DMF at ice temp-room temperature to give 84.3% (S)-3-(N-benzyloxycarbonylamino)tetrahydrofuran-2-one. This was hydrogenolyzed in EtOH over Pd/C and the product was stirred with BOC-Phe-OH, 1-hydroxybenzotriazole, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in DMF to give 78.3% (S)-3-(N-tert-butoxycarbonylphenylalanyl amino)tetrahydrofuran-2-one. The latter in THF was treated with DIBAL in PhMe at -72° to give 37.5% title compound (II). I inhibited cathepsin L with IC₅₀ = 6.9 + 10⁻⁷-8.0 + 10⁻⁹ M, and at 10-30 μM gave 26-82% inhibition of bone resorption in rat fetuses according to the method of Raisz.


IT 167765-33-5P 167765-34-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptidylactol derivs. as inhibitors of cathepsin L)

RN 167765-33-5 CAPLUS


CN Pentanamide, 4-methyl-2-[[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-hydroxy-3-furanyl)-, [2R-[2α,3α(S*)]]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 167765-34-6 CAPLUS
 CN Pentanamide, 4-methyl-2-[[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-hydroxy-3-furanyl)-, [2S-[2 α ,3 β (R*)]]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **167766-65-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of peptidyllactol derivs. as inhibitors of cathepsin L)
 RN 167766-65-6 CAPLUS
 CN Pentanamide, 4-methyl-2-[[[(1-naphthalenylamino)thioxomethyl]amino]-N-(tetrahydro-2-oxo-3-furanyl)-, [S-(R*,R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1984:138858 CAPLUS
 DN 100:138858
 TI β -Lactam compounds

IN Bognar, Rezsoe; Jaszberanyi, Csaba; Farkas, Erzsebet; Punyiczki, Maria;
 Hernadi, Ferenc; Eke, Katalin; Petrikovics, Ilona
 PA Chinoiin Gyogyszer es Vegyeszeti Termekek Gyara R. T., Hung.
 SO Ger. (East), 38 pp.
 CODEN: GEXXA8

DT Patent
 LA German

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|----------|
| PI | DD 203053 | A5 | 19831012 | DD 1982-240119 | 19820524 |
| | | | | DD 1982-240119 | 19820524 |

AB Carbamoyl, thiocarbamoyl, and selenocarbamoyl derivs. of aminoacetamidocephems and aminoacetamidopenams were prepared. Thus, cephalexin was treated with PhNCS to give I which had min. inhibitory concentrate against Bacillus cereus β -lactamase of $< 0.32 \mu\text{M}$.

IT 84381-39-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and β -lactamase-inhibiting activity of)

RN 84381-39-5 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-methyl-8-oxo-7-[[phenyl[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]
 aminolacetyl]amino]-, [6R-[6 α ,7 β (R*)]]-, compd. with
 N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-38-4

CMF C24 H21 F3 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



IT 84380-85-8P 84381-37-3P 84381-41-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 84380-85-8 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-7-[[[(1-naphthalenylamino)thioxomethyl]amino]phenylacetyl]amino]-
8-oxo-, [6R-[6 α ,7 β (R*)]]-, compd. with N,N-diethylethanamine
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84380-84-7

CMF C27 H24 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



RN 84381-37-3 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-8-oxo-7-[[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]
amino]acetyl]amino]-, [6R-[6 α ,7 β (R*)]]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-36-2

CMF C24 H21 F3 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



RN 84381-41-9 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-7-[[[(3-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino
]-8-oxo-, [6R-[6 α ,7 β (R*)]]-, compd. with N,N-diethylethanamine
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-40-8


CMF C23 H21 N5 O6 S2

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



L7 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1983:71804 CAPLUS
DN 98:71804
TI β -Lactam derivatives and pharmaceutical compositions containing them
PA Chinoin Gyogyszer es Vegyeszeti Termek Gyara Rt. , Hung.
SO Belg., 39 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-------------|------|----------|-----------------|------------|
| PI | BE 893057 | A1 | 19820830 | BE 1982-207990 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | HU 33811 | O | 19841228 | HU 1981-1154 | 19810504 |
| | SE 8202674 | A | 19821105 | SE 1982-2674 | 19820428 |
| | | | | HU 1981-1154 | A 19810504 |
| | DE 3215941 | A1 | 19830505 | DE 1982-3215941 | 19820429 |
| | | | | HU 1981-1154 | A 19810504 |
| | DK 8201982 | A | 19821105 | DK 1982-1982 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | FI 8201551 | A | 19821105 | FI 1982-1551 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | NO 8201456 | A | 19821105 | NO 1982-1456 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | AU 8283212 | A1 | 19821111 | AU 1982-83212 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | NL 8201810 | A | 19821201 | NL 1982-1810 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | FR 2509311 | A1 | 19830114 | FR 1982-7659 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | ES 511884 | A1 | 19830816 | ES 1982-511884 | 19820503 |
| | | | | HU 1981-1154 | A 19810504 |
| | GB 2101586 | A | 19830119 | GB 1982-12825 | 19820504 |
| | | | | HU 1981-1154 | A 19810504 |
| | JP 58013590 | A2 | 19830126 | JP 1982-73490 | 19820504 |
| | | | | HU 1981-1154 | A 19810504 |

AB β -Lactams I [X = O, S, Se; R = substituted amino, substituted hydrazino; R1-R4 = H, alkyl, (un)substituted Ph; R5 = Me, CH₂OAc, heterocyclylthiomethyl; n = 0, 1], their S-oxides and dioxides and penicillin analogs (61 compds.) were prepared. Thus cephalixin was treated with 4-MeC₆H₄NCS to give I (X = S, R = 4-MeC₆H₄NH, R1 = R3 = H, R4 = Ph, R5 = Me, n = 0) as its NEt₃ salt which gave 50% inhibition of Escherichia coli β -lactamase at 43.19 μ mol.

IT 84381-39-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and β -lactamase inhibiting activity of)

RN 84381-39-5 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-8-oxo-7-[[phenyl[[thioxo[[3-(trifluoromethyl)phenyl]amino]methyl]
amino]acetyl]amino]-, [6R-[6 α ,7 β (R*)]]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-38-4

CMF C24 H21 F3 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



IT 84380-85-8P 84381-37-3P 84381-41-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 84380-85-8 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-7-[[[(1-naphthalenylamino)thioxomethyl]amino]phenylacetyl]amino]-
8-oxo-, [6R-[6 α ,7 β (R*)]]-, compd. with N,N-diethylethanamine
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84380-84-7

CMF C27 H24 N4 O4 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



RN 84381-37-3 CAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-methyl-8-oxo-7-[[phenyl[[thioxo[[2-(trifluoromethyl)phenyl]amino]methyl]
amino]acetyl]amino]-, [6R-[6 α ,7 β (R*)]]-, compd. with
N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-36-2

CMF C24 H21 F3 N4 O4 S2


Absolute stereochemistry..



CM 2

CRN 121-44-8

CMF C6 H15 N




RN 84381-41-9 CAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-methyl-7-[[[(3-nitrophenyl)amino]thioxomethyl]amino]phenylacetyl]amino
]-8-oxo-, [6R-[6 α ,7 β (R*)]]-, compd. with N,N-diethylethanamine
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 84381-40-8

CMF C23 H21 N5 O6 S2


Absolute stereochemistry.



CM 2

CRN 121-44-8

CMF C6 H15 N



L7 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1981:65461 CAPLUS
 DN 94:65461
 TI 4-Unsubstituted azetidinone derivatives
 IN Hashimoto, Masashi; Hemmi, Keiji; Kamiya, Takashi; Komori, Tadaaki;
 Nakaguti, Osamu; Saito, Yoshihisa; Shiokawa, Youichi; Takasugi, Hisahi;
 Takaya, Takao; Teraji, Tsutomu
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO U.S., 130 pp. Cont.-in-part of U.S. Ser. No. 694,891, abandoned.
 CODEN: USXXAM
 DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|------|----------|-----------------|-------------|
| PI | US 4207234 | A | 19800610 | US 1977-858375 | 19771207 |
| | | | | US 1975-593668 | A2 19750707 |
| | | | | US 1976-694891 | A2 19760610 |
| | US 4472300 | A | 19840918 | US 1980-130205 | 19800313 |
| | | | | US 1975-593668 | A2 19750707 |
| | | | | US 1976-694891 | A2 19760610 |
| | | | | US 1977-858375 | A3 19771207 |

OS CASREACT 94:65461


AB Lactacillanic acids and analogs I (R = NH₂, acylamino, benzenesulfonamido; R₁ = CO₂H, pharmaceutically acceptable salt or ester derivative of CO₂H; R₂ = H, NH₂, NO₂, halo, alkoxy, alkylthio; R₃ = H, OH, alkyl, alkylthio, OCH₂Ph; R₄ = H, Halo, alkoxy, alkylthio), which showed bactericidal activity, were prepared. Thus, 3-aminolactacillanic acid reacted with PhCH₂COCl in water-Me₂CO containing NaHCO₃ to yield I (R = PhCH₂CONH, R₁ = CO₂H, R₃ = OH, R₂ = R₄ = H).

IT 59510-75-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(deacylation of)

RN 59510-75-7 CAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)





IT 59510-76-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deacylation of)

RN 59510-76-8 CAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-carboxy-3-[[[(1-naphthalenylamino)thioxomethyl]amino]propoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]-α-(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




IT 59510-75-7P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 59510-75-7 CAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][(1-naphthalenylamino)thioxomethyl]amino]acetyl]ami

no] - α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

L7 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1980:181065 CAPLUS
 DN 92:181065
 TI Studies on heterocyclic compounds. Preparation of N1-(4-arylthiazol-2-ylacetyl-amino)-N2-aryl and N1-(substituted benzothiazol-2-ylacetyl-amino)-N2-aryl thioureas
 AU Dash, B.; Praharaj, S.; Mohapatra, P. K.
 CS Dep. Chem., Utkal Univ., Bhubaneswar, 751 004, India
 SO Journal of the Institution of Chemists (India) (1979), 51(4), 151-5
 CODEN: JOICA7; ISSN: 0020-3254
 DT Journal
 LA English
 OS CASREACT 92:181065
 AB Thioureas I and II (R = H, Me, Cl, OMe; R1 = optionally substituted Ph, 1-naphthyl; R2 = H, 6-Me, 6-Cl, 6-NO2, 6-Ph, 5-NO2, 4-OMe) were obtained by treating the thiazoleamines with ClCH2COCl and R1NHCSNH2. At 500 ppm I and II caused 60.2-88.8% inhibition of Helminthosporium sativum growth.
 IT **73458-16-9P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and fungicidal activity of)
 RN 73458-16-9 CAPLUS
 CN Acetamide, 2-[[[(1-naphthalenylamino)thioxomethyl]amino]-N-(4-phenyl-2-thiazolyl)]- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1976:421078 CAPLUS
 DN 85:21078
 TI Azetidinone derivatives
 IN Kamiya, Takashi; Yoshihisa, Takarazuka; Hashimoto, Masashi; Teraji,
 Tsutomu; Takaya, Takao; Komori, Tadaaki; Nakaguti, Osamu; Oku, Teruo;
 Shiokawa, Youichi; et al.
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Ger. Offen., 318 pp.
 CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-------------|------|----------|-----------------|------------|
| PI | DE 2529941 | A1 | 19760408 | DE 1975-2529941 | 19750704 |
| | | | | JP 1974-77091 | A 19740704 |
| | | | | JP 1974-85526 | A 19740724 |
| | | | | JP 1974-88452 | A 19740731 |
| | | | | JP 1975-2650 | A 19741223 |
| | JP 51125061 | A2 | 19761101 | JP 1974-77091 | 19740704 |
| | | | | | A |
| | JP 51125062 | A2 | 19761101 | JP 1974-85526 | 19740724 |
| | | | | | A |
| | JP 51125064 | A2 | 19761101 | JP 1974-88452 | 19740731 |
| | | | | | A |
| | JP 51075056 | A2 | 19760629 | JP 1975-2650 | 19741223 |
| | | | | | A |
| | BE 830934 | A1 | 19760102 | BE 1975-157924 | 19750702 |
| | | | | JP 1974-77091 | A 19740704 |
| | CH 618161 | A | 19800715 | CH 1975-8634 | 19750702 |
| | | | | JP 1974-77091 | A 19740704 |
| | DK 7503023 | A | 19760105 | DK 1975-3023 | 19750703 |
| | | | | JP 1974-77091 | A 19740704 |

| | | | | |
|------------|---|----------------|---|----------|
| | | JP 1974-85526 | A | 19740724 |
| | | JP 1974-88452 | A | 19740731 |
| | | JP 1974-100159 | A | 19740830 |
| | | JP 1974-101712 | A | 19740902 |
| | | JP 1974-102288 | A | 19740904 |
| | | JP 1974-136561 | A | 19741126 |
| | | JP 1974-138137 | A | 19741129 |
| | | JP 1975-2650 | A | 19741223 |
| | | JP 1975-3779 | A | 19741225 |
| | | JP 1975-1272 | A | 19741228 |
| | | JP 1975-16584 | A | 19750207 |
| | | JP 1975-18241 | A | 19750212 |
| | | JP 1975-30356 | A | 19750312 |
| | | JP 1975-32702 | A | 19750317 |
| | | JP 1975-32703 | A | 19750317 |
| | | JP 1975-33292 | A | 19750318 |
| | | JP 1975-34830 | A | 19750319 |
| | | JP 1975-33821 | A | 19750320 |
| | | JP 1975-33822 | A | 19750320 |
| FI 7501949 | A | FI 1975-1949 | | 19750703 |
| | | JP 1974-77091 | A | 19740704 |
| | | JP 1974-85526 | A | 19740724 |
| | | JP 1974-88452 | A | 19740731 |
| | | JP 1974-100159 | A | 19740830 |
| | | JP 1974-101712 | A | 19740902 |
| | | JP 1974-102288 | A | 19740904 |
| | | JP 1974-136561 | A | 19741126 |
| | | JP 1974-138137 | A | 19741129 |
| | | JP 1975-2650 | A | 19741223 |
| | | JP 1975-3779 | A | 19741225 |
| | | JP 1975-1272 | A | 19741228 |
| | | JP 1975-16584 | A | 19750207 |
| | | JP 1975-18241 | A | 19750212 |
| | | JP 1975-30356 | A | 19750312 |
| | | JP 1975-32702 | A | 19750317 |
| | | JP 1975-32703 | A | 19750317 |
| | | JP 1975-33292 | A | 19750318 |
| | | JP 1975-34830 | A | 19750319 |
| | | JP 1975-33821 | A | 19750320 |
| | | JP 1975-33822 | A | 19750320 |
| NO 7502419 | A | NO 1975-2419 | | 19750703 |
| | | JP 1974-77091 | A | 19740704 |
| | | JP 1974-85526 | A | 19740724 |
| | | JP 1974-88452 | A | 19740731 |
| | | JP 1974-100159 | A | 19740830 |
| | | JP 1974-101712 | A | 19740902 |
| | | JP 1974-102288 | A | 19740904 |
| | | JP 1974-136561 | A | 19741126 |
| | | JP 1974-138137 | A | 19741129 |
| | | JP 1975-2650 | A | 19741223 |
| | | JP 1975-1272 | A | 19741228 |
| | | JP 1975-16584 | A | 19750207 |
| | | JP 1975-18241 | A | 19750212 |
| | | JP 1974-30356 | A | 19750312 |
| | | JP 1975-32702 | A | 19750317 |
| | | JP 1975-32703 | A | 19750317 |
| | | JP 1975-33292 | A | 19750318 |
| | | JP 1975-34830 | A | 19750319 |

| | | | | | |
|------------|----|----------|----------------|---|----------|
| | | | JP 1975-33821 | A | 19750320 |
| | | | JP 1975-33822 | A | 19750320 |
| FR 2278335 | A1 | 19760213 | FR 1975-20990 | | 19750703 |
| FR 2278335 | B1 | 19821217 | | | |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1975-2650 | A | 19741223 |
| SE 428799 | B | 19830725 | SE 1975-7683 | | 19750703 |
| SE 428799 | C | 19831103 | | | |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1974-100159 | A | 19740830 |
| | | | JP 1974-101712 | A | 19740902 |
| | | | JP 1974-102288 | A | 19740904 |
| | | | JP 1974-136561 | A | 19741126 |
| | | | JP 1974-138137 | A | 19741129 |
| | | | JP 1975-2650 | A | 19741223 |
| NL 7508008 | A | 19760106 | NL 1975-8008 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| AU 7582778 | A1 | 19770106 | AU 1975-82778 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1974-100159 | A | 19740830 |
| | | | JP 1974-101712 | A | 19740902 |
| | | | JP 1974-102288 | A | 19740904 |
| | | | JP 1974-136561 | A | 19741126 |
| | | | JP 1974-138137 | A | 19741129 |
| | | | JP 1975-2650 | A | 19741223 |
| | | | JP 1975-3779 | A | 19741225 |
| | | | JP 1975-1272 | A | 19741228 |
| | | | JP 1975-16584 | A | 19750207 |
| | | | JP 1975-18241 | A | 19750212 |
| | | | JP 1975-30356 | A | 19750312 |
| | | | JP 1975-32702 | A | 19750317 |
| | | | JP 1975-32703 | A | 19750317 |
| | | | JP 1975-33292 | A | 19750318 |
| | | | JP 1975-34830 | A | 19750319 |
| | | | JP 1975-33821 | A | 19750320 |
| | | | JP 1975-33822 | A | 19750320 |
| ES 439134 | A1 | 19770301 | ES 1975-439134 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| ZA 7504306 | A | 19770525 | ZA 1975-4306 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| GB 1519495 | A | 19780726 | GB 1975-28394 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1975-2650 | A | 19741223 |
| HU 172476 | P | 19780928 | HU 1975-FU336 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| AT 7505170 | A | 19790715 | AT 1975-5170 | | 19750704 |
| AT 355034 | B | 19800211 | | | |
| | | | JP 1974-77091 | A | 19740704 |

| | | | | | |
|------------|----|----------|----------------|---|----------|
| CA 1063108 | A1 | 19790925 | CA 1975-230828 | | 19750704 |
| | | | JP 1974-77091 | A | 19740704 |
| AT 7806099 | A | 19790915 | AT 1978-6099 | | 19780822 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | AT 1975-5170 | A | 19750704 |
| AT 7806098 | A | 19800415 | AT 1978-6098 | | 19780822 |
| AT 359514 | B | 19801110 | | | |
| | | | JP 1974-85526 | A | 19740724 |
| | | | AT 1975-5170 | A | 19750704 |
| SE 7903460 | A | 19790419 | SE 1979-3460 | | 19790419 |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1974-100159 | A | 19740830 |
| | | | JP 1974-101712 | A | 19740902 |
| | | | JP 1974-102288 | A | 19740904 |
| SE 7903504 | A | 19790420 | SE 1979-3504 | | 19790420 |
| | | | JP 1974-77091 | A | 19740704 |
| | | | JP 1974-88452 | A | 19740731 |
| | | | JP 1974-100159 | A | 19740830 |
| | | | JP 1974-101712 | A | 19740902 |
| | | | JP 1974-102288 | A | 19740904 |
| | | | JP 1974-136561 | A | 19741126 |
| CH 637924 | A | 19830831 | CH 1980-5357 | | 19800711 |
| | | | JP 1974-85526 | A | 19740724 |
| | | | CH 1975-8634 | A | 19750702 |

PATENT FAMILY INFORMATION:

FAN 1977:139821

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|-------------|------|----------|-----------------|------------|
| PI | JP 51110556 | A2 | 19760930 | JP 1975-36267 | 19750325 |
| | JP 51029476 | A2 | 19760312 | JP 1974-100159 | A 19740830 |
| | JP 51029477 | A2 | 19760312 | JP 1974-101712 | A 19740902 |
| | JP 51029478 | A2 | 19760312 | JP 1974-102288 | A 19740904 |
| | JP 51125065 | A2 | 19761101 | JP 1974-136561 | A 19741126 |
| | JP 51125271 | A2 | 19761101 | JP 1974-138137 | A 19741129 |
| | JP 51075057 | A2 | 19760629 | JP 1975-3779 | A 19741225 |
| | JP 51125272 | A2 | 19761101 | JP 1975-1272 | A 19741228 |
| | JP 51091249 | A2 | 19760810 | JP 1975-16584 | A 19750207 |
| | JP 51095056 | A2 | 19760820 | JP 1975-18241 | A 19750212 |
| | JP 51105052 | A2 | 19760917 | JP 1975-30356 | A 19750312 |
| | JP 51108054 | A2 | 19760925 | JP 1975-32702 | A 19750317 |
| | JP 51108055 | A2 | 19760925 | JP 1975-32703 | A 19750317 |
| | JP 51122058 | A2 | 19761025 | JP 1975-33292 | A 19750318 |

| | | | | |
|-------------|----|----------|----------------|------------|
| JP 51108059 | A2 | 19760925 | JP 1975-34830 | 19750319 |
| | | | A | |
| JP 51108057 | A2 | 19760925 | JP 1975-33821 | 19750320 |
| | | | A | |
| JP 51108058 | A2 | 19760925 | JP 1975-33822 | 19750320 |
| | | | A | |
| DK 7902705 | A | 19790626 | DK 1979-2705 | 19790626 |
| | | | JP 1974-77091 | A 19740704 |
| | | | JP 1974-88452 | A 19740731 |
| | | | JP 1974-100159 | A 19740830 |
| | | | JP 1974-101712 | A 19740902 |
| | | | JP 1974-102288 | A 19740904 |
| | | | JP 1974-136561 | A 19741126 |
| | | | JP 1974-138137 | A 19741129 |
| | | | JP 1975-2650 | A 19741223 |
| | | | JP 1975-3779 | A 19741225 |
| | | | JP 1975-1272 | A 19741228 |
| | | | JP 1975-16584 | A 19750207 |
| | | | JP 1975-18241 | A 19750212 |
| | | | JP 1975-30356 | A 19750312 |
| | | | JP 1975-32702 | A 19750317 |
| | | | JP 1975-32703 | A 19750317 |
| | | | JP 1975-33292 | A 19750318 |
| | | | JP 1975-34830 | A 19750319 |
| | | | JP 1975-33821 | A 19750320 |
| | | | JP 1975-33822 | A 19750320 |
| | | | JP 1975-36267 | A 19750325 |


AB After the antibiotic FR-1923 (obtained from fermentation liquor of Nocardia) was identified as I, 543 analogs [II; R = NH₂ or acylamino; R₁ = alkyl (saturated or unsatd., straight-chain or branched) with substituents, e.g., CO₂H (or its derivs.), CN, OH, NH₂, Ph or substituted Ph] were prepared by standard procedures and shown to be effective against, e.g., Bacillus subtilis, Escherichia coli, and Staphylococcus aureus.

IT **59510-75-7P 59510-76-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 59510-75-7 CAPLUS


CN 1-Azetidineacetic acid, 3-[[[4-[3-(acetylamino)-3-carboxypropoxy]phenyl][[(1-naphthalenylamino)thioxomethyl]amino]acetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)




RN 59510-76-8 CAPLUS

CN 1-Azetidineacetic acid, 3-[[[4-[3-carboxy-3-[[[1-naphthalenylamino]thioxomethyl]amino]propoxy]phenyl] [[1-naphthalenylamino]thioxomethyl]amino]acetyl]amino]- α -(4-hydroxyphenyl)-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A





=>